Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights

Business Wire May 14, 2019

Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis

Business Wire May 10, 2019

Aurinia Pharmaceuticals to Release First Quarter 2019 Financial Results on May 14, 2019

Business Wire May 9, 2019

Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen

Business Wire April 30, 2019

Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen

Press Releases April 30, 2019

Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 24, 2019

Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board

Business Wire April 11, 2019

Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

Business Wire March 19, 2019

Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease

Business Wire March 14, 2019

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019

Business Wire March 7, 2019

Aurinia Closes At-The-Market Facility

Business Wire February 27, 2019

Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis

Business Wire February 25, 2019

Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City

Business Wire February 20, 2019

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

Business Wire January 22, 2019

Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome

Business Wire January 21, 2019

Thinking about buying stock in Aurinia Pharmaceuticals Inc, Eagle Bancorp, Canada Goose Holdings Inc., New Age Beverages Corp, or vTv Therapeutics Inc.?

PR Newswire December 31, 2018

Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

Business Wire December 19, 2018

Aurinia Establishes at-the-Market Facility

Business Wire November 30, 2018

Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire November 27, 2018

Aurinia to Participate in November Investor Conferences

Business Wire November 9, 2018